http://www.lsis.com/goto/r60/rss 2010-06-23T11:10:30+01:00 text/html http://www.biospace.com BioSpace http://www.lsis.com/goto/v60/%3B%97g%FC%1C%7C%7D%7B Press Release - Exosome Diagnostics, Inc., http:/www.ExosomeDX.com, the developer of minimally-invasive molecular diagnostics, today announced that it has raised $20 million co-led by NGN Capital (www.ngncapital.com, ( NGN ) New York, and Forbion Capital Partners www.forbion.com, ( Forbion ) Naarden, The Netherlands, to further develop and commercialize a series of next-generation body fluid based oncology diagnostics through its proprietary, exosome based technology platform. The trans-atlantic Company is establishing R&D and service operations in New York and Munich. Exosomes are lipid-covered microvesicles shed by solid tumors into bodily fluids, such as blood and urine. Tumor (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/goto/v60/%3B%97a%F7%10%7F%7Bz MALVERN, Pa.-(BUSINESS WIRE)-Promedior, Inc., a clinical stage biotechnology company developing novel therapies to treat inflammatory and fibrotic diseases, today announced that it has raised $12 million in a Series C financing round. Forbion Capital Partners led the round, with participation from existing investors Morgenthaler Ventures, HealthCare Ventures, Polaris Venture Partners, and Easton Capital. The Series C financing brings the total capital raised by Promedior over the past year to $27 million. Proceeds from the Series C financing will enable Promedior to accelerate the development of its pipeline and expand the clinical development program for its lead drug candidate, (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v60/%3B%96j%F8%17%7C%7Ey OBJECTIVE: MMP-13 is highly upregulated in arthritis and therefore strongly implicated in the pathogenesis of osteoarthritis (OA). Selective inhibition of MMP-13 may provide the desired cartilage degradation protection, while overcoming the musculoskeletal toxicity seen with nonselective inhibition of MMPs. METHODS: Activity and selectivity of novel MMP-13 inhibitors were determined in enzymatic and collagenase assays. Inhibition kinetics and competitive binding experiments were performed. The inhibition of collagen degradation was studied in cartilage explants from OA patients and in bovine and human articular cartilage systems. RESULTS: We have identified a new class of very potent and (…) text/html http://www.prnewswire.com PR Newswire http://www.lsis.com/goto/v60/%3B%96j%FC%17u%7Bx Third Quarter 2009 Revenue Decreased 2 Percent to $3.8 BillionThird Quarter 2009 GAAP Earnings Per Share Increased 30 Percent to $1.36Reaffirmed 2009 Total Revenue Trending Towards Upper End of Current Guidance Range of $14.4-$14.8 Billion2009 Adjusted Earnings Per Share Guidance Range of $4.80-$4.95 Raised to $4.90-$5.05 Download image THOUSAND OAKS, Calif., Oct. 21 /PRNewswire-FirstCall/ - Amgen (Nasdaq: AMGN) reported adjusted earnings per share (EPS) of $1.49 for the third quarter of 2009, an increase of 21 percent compared to $1.23 for the third quarter of 2008. Adjusted net income increased 16 percent to $1,518 million in the third quarter of 2009 compared to $1,308 million in the (…) text/html http://www.bionity.com Bionity.com http://www.lsis.com/goto/v60/%3B%96j%FC%14zx%7C 18.06.2009 - According to Frost & Sullivan, the pharmaceutical industry had witnessed a huge wave of mergers and acquisitions activities in the past decade. Recently, there has been a surge in M&A activities, especially mega-M&As. Clearly, the current economic downturn, compounded by the credit crunch, has had an impact. However, this factor alone cannot be attributed to the recent M&A mania which includes four mega M&As in the first half of 2009. Big pharma historically has been fighting with little success, on various issues like patent expiry of blockbuster molecules, regulatory hurdles, generics competition, under utilization of resources, declining product pipeline due to a low R&D (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v60/%3B%96j%FD%1Cuwx UTRECHT, Netherlands & CAMBRIDGE, England-(BUSINESS WIRE)-PanGenetics, an antibody development company which is developing PG110, a humanized antibody to Nerve Growth Factor (NGF), today announced it has entered into an agreement with Abbott (NYSE: ABT) under which Abbott will acquire the global rights to this novel biologic. PG110 is currently in a Phase 1 clinical trial in patients with osteoarthritis and represents a promising new therapeutic for the treatment of chronic pain. The agreement includes an upfront payment of $170 million plus additional milestone payments, for a total of up to $190 million. Kevin Johnson, CEO of PanGenetics, commented: We are very pleased to hand the keys (…) text/html http://www.prnewswire.com PR Newswire http://www.lsis.com/goto/v60/%3B%96k%FF%10%7Cw%7C ROTTERDAM, The Netherlands, September 10 /PRNewswire/ - arGEN-X BV, a biopharmaceutical company focused on the discovery and development of human antibodies using its proprietary SIMPLE Antibody(TM) platform, today announced the successful first closing of its Series A equity financing round. The Company raised EUR 9.5million (~ USD 13.6 million) from a syndicate of leading life science investors. The financing round is one of the largest of its kind in the last 12 months. The deal was co-led by Forbion Capital Partners (The Netherlands) and LSP (Life Sciences Partners - The Netherlands). Christina Takke for Forbion Capital Partners and John de Koning for LSP have joined the arGEN-X (…) text/html http://www.prnewswire.com PR Newswire http://www.lsis.com/goto/v60/%3B%96e%F7%13uwr Second Quarter 2009 Revenue Decreased 1 Percent to $3.7 BillionSecond Quarter 2009 GAAP Earnings Per Share Increased 49 Percent to $1.252009 Total Revenue Trending Towards Upper End of Current Guidance Range of $14.4-$14.8 Billion2009 Adjusted Earnings Per Share Guidance Range of $4.55-$4.75 Raised to $4.80-$4.95 THOUSAND OAKS, Calif., July 27 /PRNewswire-FirstCall/ - Amgen (Nasdaq: AMGN) reported adjusted earnings per share (EPS) of $1.29 for the second quarter of 2009, an increase of 13 percent compared to $1.14 for the second quarter of 2008. Adjusted net income increased 6 percent to $1,311 million in the second quarter of 2009 compared to $1,235 million in the second quarter of 2008. (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v60/%3B%96e%F7%13%7B%7Fr NEW YORK-(BUSINESS WIRE)-Reportlinker.com announces that a new market research report is available in its catalogue. Reportlinker Adds Amgen Inc.: PharmaVitae Profile http:/www.reportlinker.com/p0132995/Reportlinker-Adds-Amgen-Inc-PharmaVitae-Profile.html Introduction This analysis examines the historical and forecast performance for Amgen in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information. Reasons to Purchase (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v60/%3B%96e%F9%15%7Ex%7C NEW YORK-(BUSINESS WIRE)-Reportlinker.com announces that a new market research report is available in its catalogue. Reportlinker Adds Prescription Drugs http:/www.reportlinker.com/p0131233/Reportlinker-Adds-Prescription-Drugs.html This report analyzes the worldwide markets for Prescription Drugs in US$ Billion by the following therapeutic class Oncologics/ Cancer Drugs, Lipid Regulators, Respiratory Agents, Proton Pump Inhibitors, Antidiabetics, Antipsychotics, Antidepressants, Angiotensin II Antagonists, Anti-Epileptics, Autoimmune Agents, and Others. The report provides separate comprehensive analytics for the US Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v60/%3B%96e%FD%16x%7Cx OBJECTIVE: Matrix metalloproteinases (MMPs) have long been considered excellent targets for osteoarthritis (OA) treatment. However, clinical utility of broad-spectrum MMP inhibitors developed for this purpose has been restricted by dose-limiting musculoskeletal side effects observed in humans. This study was undertaken to identify a new class of potent and selective MMP-13 inhibitors that would provide histologic and clinical efficacy without musculoskeletal toxicity. METHODS: Selectivity assays were developed using catalytic domains of human MMPs. Freshly isolated bovine articular cartilage or human OA cartilage was used in in vitro cartilage degradation assays. The rat model of (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v60/%3B%96f%F9%11%7Eyz CAMBRIDGE, Mass.-(BUSINESS WIRE)-Zafgen, Inc., a private venture-backed biopharmaceutical company focused on developing novel obesity therapeutics, today announced the appointment of Matthias Jaffe to chief financial officer and vice president of business development. Mr. Jaffe brings to Zafgen extensive finance, acquisition and business development experience. I am very pleased to welcome Matthias to his role on our leadership team, said Thomas Hughes, Ph.D., president and chief executive officer of Zafgen. As we advance our corporate and clinical development strategy, Matthias deep financial and business development expertise will be invaluable. Mr. Jaffe brings over ten years of (…) text/html http://www.prnewswire.com PR Newswire http://www.lsis.com/goto/v60/%3B%96f%FB%13%7F%7B%7C First Quarter 2009 Revenue Decreased 8 Percent to $3.3 Billion First Quarter 2009 GAAP Earnings Per Share Decreased 3 Percent to $0.98 2009 Total Revenue Guidance Range Lowered from $14.8 to $15.2 Billion to $14.4 to $14.8 Billion 2009 Adjusted Earnings Per Share Guidance Range Maintained at $4.55 to $4.75 THOUSAND OAKS, Calif., April 23 /PRNewswire-FirstCall/ - Amgen (Nasdaq: AMGN) reported adjusted earnings per share (EPS) of $1.08 for the first quarter of 2009, a decrease of 4 percent compared to $1.12 for the first quarter of 2008. Adjusted net income decreased 8 percent to $1,120 million in the first quarter of 2009 compared to $1,218 million in the first quarter of 2008. Total (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v60/%3B%96g%F9%17x%7C%7F The mode of binding and the activity of the first two non-zinc chelating, potent, and selective inhibitors of human neutrophil collagenase are reported. The crystal structures of the catalytic domain of MMP-8, respectively complexed with each inhibitor, reveals that both ligands are deeply inserted into the primary specificity subsite S(1)', where they induce a similar conformational change of the surrounding loop that is endowed with the main specificity determinants of MMPs. Accord to this rearrangement, both inhibitors remove the floor of the pocket formed by the Y227 side-chain, rendering available an extra binding region never explored before. The present data show that potent and (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/goto/v60/%3B%96g%FA%16%7B%7F%7D Full Year 2008 Revenue Increased 2 Percent to $15.0 Billion; Fourth Quarter 2008 Revenue Flat at $3.75 BillionFull Year 2008 GAAP Earnings Per Share Increased 38 Percent to $3.90; Fourth Quarter 2008 GAAP Earnings Per Share Increased 20 Percent to $0.912009 Total Revenue Expected to be in the Range of $14.8 to $15.2 Billion2009 Adjusted Earnings Per Share Expected to be in the Range of $4.55 to $4.75THOUSAND OAKS, Calif., Jan. 26 /PRNewswire-FirstCall/ - Amgen reported adjusted earnings per share (EPS), excluding stock option expense and certain other expenses, of $1.06 for the fourth quarter of 2008, an increase of 6 percent compared to $1.00 for the fourth quarter of 2007. Adjusted net (…) text/html http://www.prnewswire.com PR Newswire http://www.lsis.com/goto/v60/%3B%96g%FA%16xw%7C Full Year 2008 Revenue Increased 2 Percent to $15.0 Billion; Fourth Quarter 2008 Revenue Flat at $3.75 Billion Full Year 2008 GAAP Earnings Per Share Increased 38 Percent to $3.90; Fourth Quarter 2008 GAAP Earnings Per Share Increased 20 Percent to $0.91 2009 Total Revenue Expected to be in the Range of $14.8 to $15.2 Billion 2009 Adjusted Earnings Per Share Expected to be in the Range of $4.55 to $4.75 THOUSAND OAKS, Calif., Jan. 26 /PRNewswire-FirstCall/ - Amgen (Nasdaq: AMGN) reported adjusted earnings per share (EPS), excluding stock option expense and certain other expenses, of $1.06 for the fourth quarter of 2008, an increase of 6 percent compared to $1.00 for the fourth quarter of (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v60/%3B%96%60%F8%1Ct%7F%7B DUBLIN, Ireland-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/e755a8/valueadded_pharma) has announced the addition of Decision Resources, Inc.'s new report "Value-Added Pharma: How to Accomplish the Impossible" to their offering. The pharma industry is constantly being told that it needs to improve its bottom line and the way it does business. Pressures are mounting for more innovative drugs, less expensive drugs, and the wider use of generics all of which translates into more value at reasonable cost (the value-added proposition). But how does the industry transform itself from where it is now to where it needs to be how does it accomplish what might (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/goto/v60/%3B%96a%F7%15y%7F%7E THOUSAND OAKS, Calif., Oct. 22 /PRNewswire-FirstCall/ - Amgen reported adjusted earnings per share (EPS), excluding stock option expense and certain other expenses, of $1.23 for the third quarter of 2008, an increase of 14 percent compared to $1.08 for the third quarter of 2007. Adjusted net income, excluding stock option expense and certain other expenses, increased 11 percent to $1,308 million in the third quarter of 2008 compared to $1,181 million in the third quarter of 2007. Stock option expense on a per share basis totaled 2 cents for both the third quarter of 2008 and the third quarter of 2007. Total revenue increased 7 percent during the third quarter of 2008 to $3,875 million (…) text/html http://www.prnewswire.com PR Newswire http://www.lsis.com/goto/v60/%3B%96a%F9%1Cx%7Br Third Quarter 2008 Revenue Increased 7 Percent to $3.9 Billion Third Quarter 2008 GAAP Earnings Per Share were $1.09, an Increase from Third Quarter 2007 GAAP Earnings Per Share of $0.18 Full Year Revenue Guidance Raised from $14.6 Billion - $14.9 Billion to $14.9 Billion - $15.2 Billion Full Year Adjusted EPS Guidance Raised from $4.25 - $4.45 to $4.45 - $4.55 THOUSAND OAKS, Calif., Oct. 22 /PRNewswire-FirstCall/ - Amgen (Nasdaq: AMGN) reported adjusted earnings per share (EPS), excluding stock option expense and certain other expenses, of $1.23 for the third quarter of 2008, an increase of 14 percent compared to $1.08 for the third quarter of 2007. Adjusted net income, excluding stock (…) text/html http://www.prnewswire.com PR Newswire http://www.lsis.com/goto/v60/%3B%96a%FA%12t%7E%7B BOSTON, Oct. 14 /PRNewswire/ - Surface Logix, a privately held biopharmaceutical company focused on using biophysical chemistry to create and develop novel small molecule drugs, is pleased to announce the appointment of Keith Dionne, Ph.D. to the position of President and Chief Executive Officer and to its Board of Directors. Dr. Dionne is a seasoned executive with nearly 20 years of leadership experience in the biotechnology industry. "We are delighted to welcome Keith at this important stage of Surface Logix's development," stated Steven Gillis, Ph.D., Managing Director at ARCH Venture Partners and Chairman of Surface Logix. "We are confident that his proven track record and depth of (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v60/%3B%96b%FB%16%7F%7F%7E DUBLIN, Ireland-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/121eac/evolving_trends_in) has announced the addition of Decision Resources, Inc.'s new report "Evolving Trends in Licensing: Strategies for Building and Retaining Value in Biotechnology Alliances" to their offering. This report features interviews with top executives and industry experts, who offer insight into current alliances and contribute to a broad perspective on the drivers of current licensing practices. As the biotechnology industry continues to evolve and mature, many biotech companies are gaining more leverage in negotiating alliances. We analyzed recent deals and interviewed (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v60/%3B%96c%FA%11uzx DUBLIN, Ireland-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/ad445d/dealmaking_and_fin) has announced the addition of Decision Resources, Inc.'s new report "Dealmaking and Financing: Mergers and Acquisitions in Key Markets" to their offering. Billion-dollar deals. Hostile takeovers. Reverse mergers. Bidding wars. All of these are signs that Big Pharma is hungry for deals and is aggressively seeking, assessing, and consummating alliances on several fronts. No facet of the biotech, specialty, or generics industries is being ignored; no technology platform, clinical product, or research program is unexplored or unexamined. Dealmaking has become the (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v60/%3B%96c%FA%17xy%7F THOUSAND OAKS, Calif.-(BUSINESS WIRE)-Amgen (NASDAQ:AMGN) reported adjusted earnings per share (EPS), excluding stock option expense and certain other expenses, of $1.14 for the second quarter of 2008, an increase of 2 percent compared to $1.12 for the second quarter of 2007. Adjusted net income, excluding stock option expense and certain other expenses, decreased 2 percent to $1,235 million in the second quarter of 2008 compared to $1,265 million in the second quarter of 2007. Stock option expense on a per share basis totaled 1 cent and 3 cents for the second quarter of 2008 and 2007, respectively. Total revenue increased 1 percent during the second quarter of 2008 to $3,764 million (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v60/%3C%95j%F6%12y%7Bs BOSTON-(BUSINESS WIRE)-Halloran Consulting Group (HCG), specialists in clinical operations management for established and emerging life sciences companies, today announced key appointments to the executive team and a restructuring of its practice areas as a result of new service offerings. Over the past year the company has expanded its client base and experienced year-on-year growth based on high demand for proven skill and expertise in clinical operations management. With the addition of key senior executives Greg Dombal and Shaghig Palanjian, HCG is adding core capabilities to its portfolio of services, positioning it to have an even stronger impact on quality development of new drugs (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v60/%3C%95j%F7%1C%7D%7B%7D NEW YORK-(BUSINESS WIRE)-Reportlinker.com announces that a new market research report related to the Cardiovascular diseases industry is available in its catalogue. The World Diabetes Market, 2006-2025 To order this report: www.reportlinker.com/p076223/2008/02/06/The-World-Diabetes-Market -2006-2025.html Diabetes affects approximately 246 million people worldwide and this number is increasing. The IDF predict 380 million diabetics by 2025. The Global Diabetes drug treatment market was valued at over $21 billion in 2006 and the market is still expanding rapidly due to the high prevalence of diabetes and lifestyle changes. You cannot afford to ignore this market. To ignore this report when (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v60/%3C%95j%F7%12x%7Fx Paclitaxel and related taxanes exhibit their anticancer activity by promoting tubulin polymerization and stabilizing microtubules, which results in mitotic G2/M arrest and apoptosis. The clinical success of paclitaxel in treating a wide array of tumor types has led to numerous efforts to identify novel natural products with paclitaxel-like mechanisms of action, but which may overcome some of the liabilities of the taxanes. Although the list of natural products that share the paclitaxel-like mechanism is relatively small, it continues to expand and currently includes a number of structurally distinct classes. Despite the mechanistic similarities between these classes, differences exist (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v60/%3C%95j%FA%1D%7Dy%7D THOUSAND OAKS, Calif.-(BUSINESS WIRE)-Amgen (NASDAQ:AMGN) reported adjusted EPS, excluding stock option expense and certain other expenses, of $1.00 in the fourth quarter of 2007, an increase of 11 percent compared to $0.90 in the fourth quarter of 2006. Adjusted net income, excluding stock option expense and certain other expenses, increased 3 percent to $1,088 million in the fourth quarter of 2007 compared to $1,060 million in the fourth quarter of 2006. Stock option expense on a per share basis totaled 3 cents in the fourth quarter of 2007 and 2006, respectively. Full year 2007 adjusted EPS, excluding stock option expense and certain other expenses, were $4.29 versus $3.90 in 2006, a 10 (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v60/%3C%95j%FE%14%7Fwy THOUSAND OAKS, Calif.-(BUSINESS WIRE)-Amgen (NASDAQ:AMGN) Chairman and Chief Executive Officer Kevin Sharer in a presentation to investors at today s JP Morgan Healthcare Conference, said that, despite regulatory and reimbursement changes affecting sales of Erythropoiesis Stimulating Agent (ESA) products, the Company expects 2007 adjusted earnings per share (EPS) to be above its previously announced (Oct. 24, 2007) guidance range of $4.13 - $4.23, and close to the low end of the Company s Jan. 25, 2007 adjusted EPS guidance of $4.30 - $4.50, excluding stock option expense and certain other expenses. Sharer stated that ESA revenue is currently stable, but acknowledged that the ESA dialogue (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v60/%3C%95d%F9%15z%7C%7D THOUSAND OAKS, Calif.-(BUSINESS WIRE)-Amgen (NASDAQ:AMGN) reported adjusted earnings per share (EPS), excluding stock option expense and certain other expenses, of $1.08 for the third quarter of 2007, an increase of 4 percent compared to $1.04 for the third quarter of 2006. Adjusted net income, excluding stock option expense and certain other expenses, decreased 4 percent to $1,181 million in the third quarter of 2007 compared to $1,224 million in the third quarter of 2006. Stock option expense on a per share basis totaled 2 cents and 3 cents for the third quarter of 2007 and 2006, respectively. Total revenue remained unchanged during the third quarter of 2007 at $3.6 billion versus the (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v60/%3C%95e%FE%11%7Fv%7D THOUSAND OAKS, Calif.-(BUSINESS WIRE)-Amgen (NASDAQ: AMGN) today announced initiatives that will reduce company staff by 12-14 percent and deliver other operational efficiencies while ensuring continued investment at industry-leading levels in research and development. These initiatives will be substantially completed by 2008 and yield pre-tax savings from prior plan of between $1.0 billion - $1.3 billion in 2008. Cumulative pre-tax restructuring charges associated with these changes are expected to be $600 million - $700 million in 2007 and 2008, which includes $289 million for asset impairment and related costs reported in the second quarter. The company also announced that adjusted (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v60/%3C%95f%F9%16y%7Cs THOUSAND OAKS, Calif.-(BUSINESS WIRE)-Amgen (NASDAQ: AMGN) reported adjusted earnings per share (EPS), excluding stock option expense and certain other expenses, of $1.12 for the second quarter of 2007, an increase of 7 percent compared to $1.05 during the second quarter of 2006. Adjusted net income, excluding stock option expense and certain other expenses, increased 2 percent to $1,265 million in the second quarter of 2007 compared to $1,235 million in the second quarter of 2006. Stock option expense on a per share basis totaled 3 cents and 4 cents in the second quarter of 2007 and 2006, respectively. Total revenue increased 3 percent during the second quarter of 2007 to $3,728 million (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v60/%3C%95f%FB%14zyy THOUSAND OAKS, Calif.-(BUSINESS WIRE)-Amgen (NASDAQ:AMGN) today announced the completion of its acquisition of Alantos, a private company developing drugs for the treatment of diabetes and inflammatory diseases. The transaction provides Amgen with Alantos s DPP-IV inhibitor in clinical development (Phase 2a) for the treatment of type II diabetes as well as its matrix metalloproteinases platform for osteoarthritis. The acquisition was originally announced June 6. About Amgen Amgen discovers, develops and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science s promise by bringing safe, effective medicines (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v60/%3C%95g%FC%12uw%7F THOUSAND OAKS, Calif., & CAMBRIDGE, Mass.-(BUSINESS WIRE)-Amgen (NASDAQ:AMGN) announced today that it has agreed to acquire Alantos, a private company developing drugs for the treatment of diabetes and inflammatory diseases. Alantos lead drug candidate, ALS 2-0426, is a DPP-IV inhibitor in clinical development (Phase 2a) for the treatment of type II diabetes. Under terms of the agreement, Amgen will pay $300 million in cash to acquire Alantos. Following completion of the transaction, Alantos will become a wholly-owned subsidiary of Amgen. The acquisition has been approved by the boards of directors of each company and the shareholders of Alantos. It is subject to customary closing (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v60/%3C%95%60%FB%11%7Cvy CAMBRIDGE, Mass.-(BUSINESS WIRE)-Dyax Corp. (Nasdaq: DYAX) announced today that Gustav A. Christensen is joining the Company as Executive Vice President and Chief Business Officer. Mr. Christensen joins Dyax s executive management team where he will oversee and lead the Company s partnering strategy as well as other business development activities such as licensing and collaboration transactions. Gustav Christensen brings a broad range of experience in advising and leading biotechnology and biopharmaceutical companies and we are extremely pleased to have someone of his talent join the Dyax team, stated Henry Blair, Chairman and Chief Executive Officer of Dyax. As our Licensing and Funded (…) text/html http://www.medicalnewstoday.com Medical News Today http://www.lsis.com/goto/v60/%3C%94d%FA%14%7Dw%7E Alantos Pharmaceuticals, a privately held biopharmaceutical company based on the discovery and development of small molecule drugs with a focus on type II diabetes and Osteoarthritis/inflammation, today announced that it has initiated a Phase 1 clinical study with its first clinical candidate, ALS 2-0426, an orally active, small molecule inhibitor of Dipeptidyl Peptidase IV (DPP-IV), for the treatment of type II diabetes. The initiation of this clinical trial marks a significant milestone for Alantos as we transition our internal research into product development, said Keith Dionne, Ph.D., Chief Executive Officer of Alantos. DPP-IV inhibitors represent a new class of treatment for diabetes (…) text/html http://www.medicalnewstoday.com Medical News Today http://www.lsis.com/goto/v60/%3C%94d%FC%11%7C%7C%7C Alantos Pharmaceuticals, a privately held biopharmaceutical company based on the discovery and development of small molecule drugs with a focus on type II diabetes and Osteoarthritis / inflammation, today announced that it has initiated a Phase 1 clinical study with its first clinical candidate, ALS 2-0426, an orally active, small molecule inhibitor of Dipeptidyl Peptidase IV (DPP-IV), for the treatment of type II diabetes. The initiation of this clinical trial marks a significant milestone for Alantos as we transition our internal research into product development, said Keith Dionne, Ph.D., Chief Executive Officer of Alantos. DPP-IV inhibitors represent a new class of treatment for (…) text/html http://www.medicalnewstoday.com Medical News Today http://www.lsis.com/goto/v60/%3C%94d%FD%12%7E%7Cx Alantos Pharmaceuticals, a privately held biopharmaceutical company based on the discovery and development of small molecule drugs with a focus on type II diabetes and Osteoarthritis/inflammation, today announced that it has initiated a Phase 1 clinical study with its first clinical candidate, ALS 2-0426, an orally active, small molecule inhibitor of Dipeptidyl Peptidase IV (DPP-IV), for the treatment of type II diabetes. The initiation of this clinical trial marks a significant milestone for Alantos as we transition our internal research into product development, said Keith Dionne, Ph.D., Chief Executive Officer of Alantos. DPP-IV inhibitors represent a new class of treatment for diabetes (…) text/html http://www.prnewswire.com PR Newswire http://www.lsis.com/goto/v60/%3C%94d%FD%12%7D%7Fx CAMBRIDGE, Mass., Aug. 16 /PRNewswire/ - Alantos Pharmaceuticals, a privately held biopharmaceutical company based on the discovery and development of small molecule drugs with a focus on type II diabetes and Osteoarthritis/inflammation, today announced that it has initiated a Phase 1 clinical study with its first clinical candidate, ALS 2-0426, an orally active, small molecule inhibitor of Dipeptidyl Peptidase IV (DPP-IV), for the treatment of type II diabetes. The initiation of this clinical trial marks a significant milestone for Alantos as we transition our internal research into product development, said Keith Dionne, Ph.D., Chief Executive Officer of Alantos. DPP-IV inhibitors (…)